Unknown

Dataset Information

0

Therapeutic plasma exchange for COVID-19-associated hyperviscosity.


ABSTRACT:

Background

Recent data suggests an association between blood hyperviscosity and both propensity for thrombosis and disease severity in patients with COVID-19. This raises the possibility that increased viscosity may contribute to endothelial damage and multiorgan failure in COVID-19, and that therapeutic plasma exchange (TPE) to decrease viscosity may improve patient outcomes. Here we sought to share our experience using TPE in the first 6 patients treated for COVID-19-associated hyperviscosity.

Study design and methods

Six critically ill COVID-19 patients with plasma viscosity levels ranging from 2.6 to 4.2 centipoise (cP; normal range, 1.4-1.8?cP) underwent daily TPE for 2-3 treatments.

Results

TPE decreased plasma viscosity in all six patients (Pre-TPE median 3.75?cP, range 2.6-4.2?cP; Post-TPE median 1.6?cP, range 1.5-1.9?cP). TPE also decreased fibrinogen levels in all five patients for whom results were available (Pre-TPE median 739?mg/dL, range 601-1188?mg/dL; Post-TPE median 359?mg/dL, range 235-461?mg/dL); D-dimer levels in all six patients (Pre-TPE median 5921?ng/mL, range 1134-60?000?ng/mL; Post-TPE median 4893?ng/mL, range 620-7518?ng/mL); and CRP levels in five of six patients (Pre-TPE median 292?mg/L, range 136-329?mg/L; Post-TPE median 84?mg/L, range 31-211?mg/L). While the two sickest patients died, significant improvement in clinical status was observed in four of six patients shortly after TPE.

Conclusions

This series demonstrates the utility of TPE to rapidly correct increased blood viscosity in patients with COVID-19-associated hyperviscosity. Large randomized trials are needed to determine whether TPE may improve clinical outcomes for patients with COVID-19.

SUBMITTER: Truong AD 

PROVIDER: S-EPMC7753437 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Recent data suggests an association between blood hyperviscosity and both propensity for thrombosis and disease severity in patients with COVID-19. This raises the possibility that increased viscosity may contribute to endothelial damage and multiorgan failure in COVID-19, and that therapeutic plasma exchange (TPE) to decrease viscosity may improve patient outcomes. Here we sought to share our experience using TPE in the first 6 patients treated for COVID-19-associated hypervi  ...[more]

Similar Datasets

| S-EPMC8250601 | biostudies-literature
| S-EPMC9741734 | biostudies-literature
| S-EPMC8495054 | biostudies-literature
| S-EPMC8244539 | biostudies-literature
| S-EPMC7447602 | biostudies-literature
| S-EPMC7754560 | biostudies-literature
| S-EPMC8776342 | biostudies-literature
| S-EPMC8402853 | biostudies-literature
| S-EPMC8652389 | biostudies-literature
| S-EPMC7983568 | biostudies-literature